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Abstract 
Objective: Worsening renal function (WRF) is common in patients treated for acute heart failure 
(AHF) and might be associated with a significant increase in blood nitrogen urea (BUN). Although 
many patients develop WRF during hospitalization, its prognostic role is still unclear. Thus, we 
aimed to evaluate the prognostic relevance of WRF according to BUN changes during 
hospitalisation.  
Methods: We studied patients with AHF screened for Diur-HF Trial (NCT01441245).  WRF was 
defined as an in-hospital rise in serum creatinine ≥ 0.3 mg/dl or estimated glomerular filtration rate 
(GFR) reduction ≥ 20%. BUN increase was defined as a rise in BUN ≥ 20% during admission. 
Effective decongestion was defined as complete resolution of two, or more, signs of HF, or absence 
of clinical signs of congestion at discharge.  
Results: Of 247 patients enrolled, 59 (23%) patients experienced WRF, 107 (43%) had a BUN 
increase >20%, and 111 (45%) were effectively decongested during hospitalization.  
During 180 days of follow-up, 136 patients died or were re-hospitalised for AHF. An increase in 
BUN was an independent predictor of adverse outcome, regardless of WRF (HR = 2.19 [1.35-3.54], 
p =0.002 and 1.71 [1.14-2.59], p =0.010; with and without WRF, respectively) or congestion at 
discharge.  WRF was not an independent predictor of outcome if BUN did not increase or when 
congestion was effectively relieved. 
Conclusions: an increase in BUN>20% during hospitalization for AHF predicts a poor outcome 
independently from renal function deterioration and decongestion.  WRF predicts adverse outcome 
only if BUN increases substantially or clinical congestion persists. 
 
Key Words: acute heart failure, outcome, renal dysfunction, blood urea nitrogen.   
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
Introduction 
Around 50% of patients admitted with acute heart failure (AHF) will die within 5 years from 
diagnosis. [1,2] Thus, there is a need to identify with more precision those clinical phenotypes at 
higher risk of adverse outcome. [3,4]  Chronic kidney disease (CKD) is one of the most potent 
contributing factors aggravating prognosis of patients with AHF. [5] CKD is common, and it might 
affect more than 50% of hospitalized patients with AHF, 10-15% of whom will have advanced 
stages of renal dysfunction. [6,7] Many studies showed that WRF during HF admission usually 
complicates a poorer cardiac, or renal, function and has a prognostic impact similar to that of CKD 
[8-10]. However, other studies did not confirm this association between WRF and prognosis: a 
transient WRF might be the results of aggressive decongestion and temporary kidney overload.  
[11-14] 
Blood nitrogen urea (BUN) is not only a marker of renal function, but it also reflects 
neurohormonal activation, that enhances reabsorption of urea in the terminal inner medullary 
collecting duct. [15] Thus, changes in BUN in the context of minor fluctuation or renal function can 
be valuable to understand when a relative intravascular volume reduction is taking place in a patient 
with congestive status. [16] With the present study, we evaluate the prognostic relevance of 
worsening renal function and BUN changes in patients admitted with AHF.  
 
Methods 
Study Design 
This is a retrospective, post-hoc analysis of a prospective single-centre study including 247 patients 
admitted with AHF who were screened for the Diur-HF Trial (clinicaltrials.gov: NCT01441245) 
between September 2013 and July 2015.  
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Diur-HF is an ongoing prospective, open-label, study comparing continuous with intermittent 
infusion of furosemide in patients admitted with a diagnosis of AHF conducted at the Departments 
of Internal Medicine and Cardiology of the University of Siena, Italy. [17]  We screened patients 
over the age of 18 years admitted with dyspnoea, evidence of volume overload and/or clinical signs 
of HF (peripheral oedema, rales, third heart sound, jugular turgor, lung congestion on chest X-ray), 
in whom a diagnosis of AHF was confirmed by elevated (>100 pg/ml) levels of B-type natriuretic 
peptide [BNP].Patients with end-stage (serum creatinine levels >4.0 mg/dL) renal disease or the 
need for renal replacement therapy (dialysis or ultrafiltration), a recent myocardial infarction 
(within thirty days of screening) or a systolic blood pressure< 80 mm Hg were excluded. We did 
not screen patients with known liver or neoplastic disease or concurrent infective disease. All 
patients gave their written informed consent. 
 
Clinical assessment and evaluation of congestion 
Two physicians assessed patients at admission and graded congestion by giving one point for the 
presence of each of the following clinical signs, regardless of their severity: pulmonary crepitations, 
third heart sound, jugular venous distention, peripheral oedema and hepatomegaly, for a total of 
maximum 5 points. [18]. Effective decongestion was defined as complete resolution of two, or 
more, clinical signs of HF, or absence of clinical signs of congestion  at discharge.  
 
Laboratory analysis 
Blood tests, including creatinine, BUN and BNP were measured from blood samples taken within 
24 hours post-admission and prior to discharge; Renal function was monitored every 48 hours .The 
estimated glomerular filtration rate (eGFR) was calculated using the four-variable Modification of 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
Diet in Renal Disease (MDRD) formula. [19] CKD was defined by creatinine > 1,4 mg/dl and/or 
eGFR < 60 ml/min/1,73 m2 .[20] A rise in serum creatinine ≥ 0.3 mg/dl or eGFR reduction ≥ 20% 
from admission to discharge were used according to conventional criteria to define WRF  [21] BUN 
increase was defined as a rise in BUN ≥20% from admission to discharge. [22] 
End Points 
1- To evaluate BUN changes with respect to WRF occurrence during hospitalization. 2- To study 
associations of  isolated BUN increase, WRF and their combination with outcome  3- To analyze 
the relationship existing among BUN, WRF and relief from congestion.  
 Follow-up 
Patients were followed for 180 days after discharge with clinical visits and telephone contacts. The 
primary outcome of interest was a composite of all-cause mortality (ACM) or HF hospitalization 
(HFH).  
 
Statistical analysis 
Categorical data are presented as number and percentages; normally distributed continuous data as 
mean + SD and non-normally distributed continuous variables as median and interquartile range. 
Patients with AHF were grouped by phenotypes according to WRF, BUN increase > or < 20% or by 
effective, or not, decongestion during hospitalisation. One-way ANOVA and Kruskal-Wallis tests 
were used to compare continuous variables between groups depending on the normality of the 
distribution, and the chi-squared test was used for categorical variables.  
Different multivariable Cox proportional hazard regression models were used to investigate the 
relationship between WRF, BUN and outcome. Multivariable models were adjusted for clinical 
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variables of interest (age, gender, hypertension, diabetes, dyslipidemia, coronary artery disease, 
CKD and smoking habits) chosen prospectively a priori. Kaplan-Meier curves with the log-rank 
statistic were used to illustrate outcome. All analyses were performed using SPSS 20.0 for 
Windows (SPSS Inc, Chicago IL). A 2-sided P value < 0.05 was considered statistically significant. 
 
Results 
Patient characteristics 
Of the 267 patients with AHF enrolled, 12 were excluded because of end-stage renal failure and 8  
were lost to follow-up, leaving a final cohort of 247 patients.  Median age was 83[76-88] years and 
123 (49%) were male; CKD at admission was prevalent in 101 patients (41%), median creatinine 
was 1.30[1.00-1.69] mg/dL, BUN 66[47-91] mg/dL and BNP 749[429-1150] pg/mL. [Table 1]  
During hospitalisation, 59 (24%) patients developed WRF and 107 (43%) an increase in BUN 
>20%. According to development of BUN increase and/or WRF patients were divided in 4 groups: 
37 patients (15%) had both BUN increase and WRF (Group A), 70 (28%) had isolated BUN 
increase (Group B), 22 (9%) had isolated WRF (Group C) and 118 (48%) patients had neither WRF 
nor BUN increase (Group D).   
Patients who developed both WRF and BUN increase and those with isolated WRF had the highest 
levels of BNP at admission, and a lower left ventricular ejection fraction (LVEF) compared to other 
two groups. [Supplementary Table 1] 
Outcome 
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 p=0.13; M-HR 1.66 [0.88-3.10], p=0.12.). Those with both WRF and BUN increase 
had the worst outcome (U-HR 2.38 [1.50-3.77], p<0.001; M-HR 2.19 [1.35-3.54], p=0.002.). [Table 
2 and Figure 1]  
Renal function trajectories and congestion 
To evaluate the impact of congestion, we divided our patients according to the BUN changes and 
persistence or not of congestion at discharge. Univariate analysis showed that BUN increase ≥ 20% 
at discharge was related to poor outcome either without effective decongestion (HR = 2.58 [1.51-
4.40]; p <0.001) and with effective decongestion  (HR = 1.91 [1.11-3.29]; p =0.02). After 
adjustment for potential confounders, multivariable analysis confirmed the previous findings (HR = 
2.70 [1.57-4.63]; p <0.001. HR=1.81 [1.04-3.14]; p=0.035). [Supplementary Table 2 and Figure 2] 
We performed  a further analysis evaluating the associations of incident WRF, congestion and 
outcome, and we observed that WRF was related to poor prognosis only if an effective 
decongestion was not achieved (Univariate HR = 2.14 [1.31-3.51]; p =0.001. Multivariable 
HR=2.20 [1.32-3.68]; p=0.003). [Supplementary Table 2 and Supplementary Figure 1]  
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Discussion 
Our study, conducted in a daily life clinical scenario, shows that WRF  is common in patients 
treated for AHF, but an increase in BUN>20% from baseline is even more common. Importantly, 
we found that an increase in BUN>20% during admission is a powerful predictor of adverse 
outcome;  WRF has a significant prognostic impact only if associated with an increase in BUN or 
with the inability to control clinical congestion. Interestingly, our results  suggest that caution is 
needed when relief from congestion causes a disproportionate increase in BUN.  
The bidirectional relation existing between heart and kidneys is well known, however the 
prevalence, and incidence, of renal dysfunction in patients with chronic and AHF is poorly reported 
in clinical trials and observational studies. Studies rarely provide a definition of renal dysfunction, 
and different specific phenotype of renal dysfunction might be contemplated, with different impact 
on clinical outcomes  [23]. Importantly, no universal agreement exists to what blood marker has to 
be used to define, and monitor, renal function. Our findings demonstrated that patients experiencing 
BUN increase have also an higher  prevalence of unfavorable condition such as CAD, atrial 
fibrillation and advanced CKD stage that could potentially impair outcome, although multivariable 
analysis showed that BUN is independently related to adverse event. 
Otherwise, some might argue that BUN is not a specific renal marker, as it might reflect an 
increased neurohormonal activity and the effects of vasopressin (AVP) enhancing reabsorption of 
urea at the distal tubule. [16] Acute arterial underfilling and overdiuresis, occurring during 
aggressive treatment with diuretics, could further activate the sympathetic and AVP systems, and 
subsequently increase BUN levels. Importantly, circulating BUN is also elevated secondary to an 
increased protein catabolism, as it might happen during cachexia, which could further contribute to 
an adverse outcome.   
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Our results appears confirmatory of previous multicenter trials conducted in the acute and chronic 
heart failure setting: in the OPTIME trial, a significant increase (>25%) in BUN was frequent 
(40%) during hospitalisations for HF, and was strongly related to increased mortality. [24] 
Similarly, in the ACTIV in CHF trial, BUN, but not creatinine, was an independent predictor of 
morbidity and mortality. [25] Moreover, the RELAX trial suggested that WRF was not a powerful 
predictor of poor outcome. [26] In line with the current study,
 that a 
 was associated with a significantly higher risk of all-cause 
mortality only if  there was a concomitant elevation in BUN (>25 mg/dl) [27]. Elevated levels of 
BUN are also powerful predictors of adverse outcome in ambulatory patients with heart failure. 
[28].  
Worsening congestion is one of the key reasons for admission for patients with heart failure, and the 
failure of its treatment it is one of the main drivers of outcome. Metra et al. showed that WRF 
during AHF hospitalisations is associated with increased morbidity and mortality only when clinical 
congestion persists at discharge, suggesting that effective decongestion might be more important 
than changes in renal function. [29] We expanded this data, and we identified a population of 
patients with AHF in whom the risk of adverse outcome remains high even when clinical 
congestion is effectively relieved but at the expenses of a substantial rise in BUN levels. A proof of 
these concepts,  appears to be confirmed by two recent post hoc analysis from PROTECT and 
RELAX-AHF trials examining diuretic response during hospitalization phase. [26,30,31] Both 
studies showed a strict relation among poor diuretic response, renal dysfunction and congestion. In 
the RELAX-AHF trial, WRF was not a predictor of poor outcome, conversely BUN increase was 
strictly related to reduced diuretic response confirming  the hypothesis that  the primarily driver of 
Cardio-Renal Syndrome indwells at tubular level. [26] Higher levels of BUN were also one of the 
strongest predictors of reduced diuretic response in the PROTECT trial, supporting the concept that 
sustained activation of the neuro-hormonal system might increase urea reabsorption in the kidneys,  
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which  might precede a detectable deterioration in renal function due to hypoperfusion. [31] . 
Finally, creatinine and eGFR are the two biomarkers currently involved in WRF diagnosing, 
unfortunately both parameters are  not useful to precociously recognize WRF.  In addition, they are 
not able to  identify the causes of the underlying sudden renal deterioration (i.e tubular, glomerular, 
or collector duct).  [23] Most of patients with reduced natriuretic and diuretic response  experienced 
some degree of tubular damage and renal sodium avidity. Interestingly, patients with CKD 
displayed a better diuretic response compared to patients with preserved renal function. [32,33]   
 
This peculiar finding confirms that previously described by Testani and colleagues in a population 
of stable patients with heart failure and reduced LVEF. [34] They found that use of high doses of 
loop diuretics is only associated with mortality in patients with elevated BUN (>21.0 mg/dl), which 
might reflect a significant activation of the neuro-endocrine system.  
In patients with acute heart failure, cardio-renal dysfunction and neuro-hormonal activation are 
relevant features together with systemic congestion. Although loop diuretic are the main drug to 
reduce congestion, they could potentially contribute to activate neuro-hormonal with both increase 
in sodium concentration in the macula densa and afferent arterial vasoconstriction. An optional 
strategy balancing volume status with modulation of sympathetic and RAA tone could lead to a 
better diuretic dose optimization. [35] 
 
 
Limitations 
This is a relatively small, single center, retrospective, observational study, with limited power. It 
was conducted in a tertiary hospital where patients admitted with AHF are usually older and with 
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more comorbidities than those enrolled in clinical trials and recent registries, which might explain 
the high morbidity and mortality during follow-up. [36] Also, only consenting patients considered 
suitable for the Diur-HF trial were screened and enrolled in this study, which introduces further 
selection bias. In addition, treating physicians were not blinded to clinical congestion, renal function 
or BUN modifications occurred during hospitalization and different therapeutic choices might have 
influenced results.  
Clinical assessment of congestion is highly subjective and it is frequent to observe disagreement 
amongst colleagues assessing congestion, particularly when this is not obvious; importantly, a 
comprehensive clinical evaluation might also take time and all these factors might have influenced 
how congestion was clinically assessed.  
Moreover, there is no specific algorithm to assess or grade congestion, and  there is no guidance for 
an objective use of loop diuretics. The use of ultrasound, for instance by measuring the inferior vena 
cava or jugular vein diameters, or other non-invasive technologies such as spectroscopy or bio-
impedance, could provide more robust methods to quantify congestion and its responses to 
administration of diuretics. [37,38]  Importantly, we did not serially assess weight changes and we 
did not measure invasively central venous pressure, right atrial pressure and left ventricle filling 
pressure, all of which would have provided further insight on the complex interactions between 
WRF, BUN and congestion.  
For all these reasons, our findings should be interpreted with caution and need to be confirmed in  
larger, less selective, prospective cohorts.  
 
Conclusions 
Blood urea nitrogen (BUN) increase>20% during hospitalization for AHF predicts a higher rate of 
adverse events after discharge, regardless of changes in renal function or clinical congestion. 
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Conversely, isolated WRF  did not demonstrate  any association with adverse outcome. If our 
findings will be confirmed in larger sample size, the role of WRF during hospitalization should be 
reviewed taking into the account BUN variability. Whether combining measurements of BUN 
levels with other ultrasound and biochemical methods quantifying congestion might be useful to 
improve outcomes, requires further investigations. 
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TABLES AND FIGURES LEGEND 
Table 1. Baseline characteristics 
Table 2. Univariate and Multivariable analysis for composite outcome prediction considering BUN 
increase and WRF groups. 
Figure 1. Kaplan Meier curves showing adverse events occurrence according BUN and WRF 
groups. 
Figure 2. Kaplan Meier curves showing adverse events occurrence according BUN increase and 
decongestion.    
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Table 1. Baseline characteristics 
All Patients 
Age (years) 83[76-88] 
Gender (n)  
Female 124 
Male 123 
Admission creatinine (mg/dl) 
Creatinine at discharge(mg/dl) 
1.30[1.00-1.69] 
1.40[1.00-1.74] 
eGFR at admission (ml/min/1,73 m2) 
eGFR at discharge (ml/min/1,73 m2) 
Admission BUN (mg/dl) 
BUN at discharge (mg/dl) 
Admission  BNP (pg/ml) 
BNP at discharge (pg/ml)    
Ejection fraction (%) 
49[37-65] 
47[33-66] 
66[47-91] 
74[49-104] 
749[429-1150] 
  441[155-781] 
35[25-43] 
Risk factors %/(n) 
               Chronic Kidney Disease 
 
41/(101) 
               Diabetes Mellitus 
               Hypertension 
36/(90) 
37/(92) 
               Dyslipidemia 
               Smokers 
               Ischemic heart disease 
               Atrial fibrillation 
WRF %/(n) 
BUN increase ≥ 20% %/(n) 
BNP decrease ≥ 30% %/(n) 
 
  35/(88) 
  23/(57) 
  41/(101) 
  28/(70) 
  24/(59) 
  43/(107) 
  66/(165) 
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Medication at admission %/(n)  
               Beta-Blockers   66%/(164) 
               Aldosterone antagonists   19%/(48) 
               Ace inhibitors 
Angiotensin receptors blockers                                         
  73%/(180) 
  27%/(67) 
               Nitrates 
  Digoxin 
  Statins 
  Thiazides 
  39%/(95) 
  10%/(37) 
  52%/(129) 
  6%/(14) 
               Loop diuretics   94%/(233) 
 
Abbreviations: BNP, B-type  natriuretic peptide; BUN , Blood urea nitrogen; eGFR, Estimated glomerular 
filtration rate; 
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Table 2. Univariate and Multivariable analysis.  
 
Abbreviations: B-type Natriuretic Peptide (BNP); Blood Urea Nitrogen (BUN); Coronary heart disease (CHD); Chronic Kidney Disease (CKD); Confidence Interval (CI); 
Hazard Ratio (HR); Worsening renal function (WRF). Two separate multivariable analyses are shown: in the first one (middle column) both BUN increase and WRF were 
simultaneously entered in the model, in the second (right column) we entered in the model the four patients’ phenotypes (according to BUN increase (> or < 20%) and WRF). 
1Models were adjusted for clinical variables of interest chosen prospectively (age, gender, and hypertension, diabetes, dyslipidemia, CHD, CKD and smoking habits).  
REHOSPITALIZATION or DEATH 
 Univariable analysis Multivariable analysis1 
Variable  HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value 
BUN increase ≥20% and WRF  2.38 (1.50-3.77) <0.001 - - 2.19 (1.35-3.54) 0.002 
BUN increase ≥20% without WRF 1.64 (1.09-2.45) 0.017 - - 1.71 (1.14-2.59) 0.010 
BUN increase <20% with WRF 1.60 (0.87-2.95) 0.13 - - 1.66 (0.88-3.10) 0.12 
BUN increase <20% without WRF Ref - - Ref 
Effective decongestion (yes vs no)  0.76 (0.54-1.08) 0.12 - - - 
CKD (yes vs no) 1.33 (0.95-1.87) 0.09 1.24 (0.85-1.79) 0.27 1.25 (0.89-1.82) 0.24 
BUN increase≥20% (vs <20%) 1.72 (1.23-2.41) 0.002 1.60 (1.13-2.27) 0.009 - 
WRF(yes vs no) 1.69 (1.17-2.44) 0.005 1.41 (0.95-2.10) 0.09 - 
BNP decrease ≥ 30% 1.04 (0.73-1.49) 0.82 - - - 
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Highlights 
 The prognostic relevance of kidney function in acute heart failure has been investigated with 
contradictory results. 
 The definition of worsening renal function may be challenged with introduction of  blood 
urea nitrogen  evaluation. 
 Worsening renal function evaluation for blood urea nitrogen values could improve acute 
cardio-renal syndrome diagnosis and identify patients with increased risk.  
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